HOME >> BIOLOGY >> NEWS
Immunex And Wyeth-Ayerst Laboratories Advance Enbrel Into Phase II/III Clinical Trial For Chronic Heart Failure

Positive Results of Phase I Study Presented At American College of Cardiology Conference

SEATTLE -- Immunex Corporation (NASDAQ:IMNX and Wyeth-Ayerst Laboratories announced today that they are beginning a Phase II/III clinical trial with ENBREL (etanercept) in chronic heart failure patients, one of the first large-scale studies undertaken to evaluate cytokine inhibition, an entirely new approach to studying chronic heart failure. This study will be based on positive results of a Phase I study presented today at the annual conference of the American College of Cardiology in New Orleans, LA.

Results of the double-blind, randomized, placebo-controlled multi-dose Phase I safety study in 47 heart failure patients demonstrated that ENBREL was well tolerated. The incidence of adverse events was similar in all treatment groups. The study was conducted by Dr. Douglas Mann and Dr. Guillermo Torre at Baylor College of Medicine, and Dr. Arthur M. Feldman at University of Pittsburgh Medical Center.

The 47 patients were New York Health Assessment (NYHA) class III-IV and were randomized to be treated for three months with twice weekly injections of either ENBREL at 5mg/m2, 12mg/m2 or placebo. At three months, measurements of clinical activity suggested consistent improvement for patients on ENBREL in NYHA classification, left ventricular ejection fraction, quality of life, and in a clinical composite score. In addition, there appeared to be a positive dose response in each of the categories above. Based on the results of the study, and additional clinical and preclinical data associating elevated TNF levels with chronic heart failure, the two companies have elected to proceed to a Phase II/III multicenter trial.

"We are pleased that the results of the multidose Phase I study supported moving into a Phase II/III multicenter trial," said Peggy Phillips, senior vic
'"/>

Contact: Pam Rabe
prabe@immunex.com
206-470-4131
Immunex Corporation
8-Mar-1999


Page: 1 2 3 4

Related biology news :

1. UWs new Cell Systems Initiative welcomes Immunex collaboration
2. Immunex Corporation and Genentech, Inc. join forces to develop TRAIL/Apo2L in cancer
3. Millennium and Wyeth-Ayerst announce the discovery of key potassium ion channel modulating proteins
4. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
5. Berlex Laboratories announces FDA approval of YASMIN (R), new oral contraceptive with unique progestin
6. FDA clears Berlex Laboratories Mirena (R), new form of long-acting contraception meets need for U.S. women
7. Advances in tumor angiogenesis Dendritic cells co-opted to the dark side
8. Advances in equine cloning may aid insight into human diseases
9. Advanced sensors, computing systems tracking sea animals worldwide
10. Lunch workshop at the American Association for the Advancement of Science (AAAS) Annual Meeting
11. Advance in developing biological strategies to produce hydrogen and sequester carbon dioxide

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 02, 2020 , ... ... has announced a publication detailing the use of its revolutionary NEXTGENPCR endpoint ... reaction (RT-PCR) in 16 minutes. The article, titled "Ultra-fast one-step RT-PCR protocol ...
(Date:6/28/2020)... ... June 25, 2020 , ... In an upcoming episode scheduled for ... Point of Care Testing solutions (POCT). Check local listings for more info. , Today, ... offices and are shipped to labs throughout the country. Results are then available several ...
(Date:6/23/2020)... ... June 22, 2020 , ... The field of quantitation of ... assays (LBA) have dominated this area. However, the use of mass spectrometry in this ... now necessitates the question “How do you choose which approach to use (LBA or ...
Breaking Biology News(10 mins):
(Date:7/7/2020)... ... 06, 2020 , ... Bio-IT World has announced the winners ... the University of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia Alliance ... highlighting outstanding examples of how technology innovations and strategic initiatives can be powerful ...
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a leading provider of sensor ... of all types to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ ... enabled business will provide a health performance index system that scores all aspects of ...
(Date:6/23/2020)... ... June 23, 2020 , ... Kerafast Inc. , developers ... announced the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The ... of SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 ...
(Date:6/23/2020)... ... 2020 , ... Nobilis Therapeutics, a biopharmaceutical company focused on ... Investigational New Drug application (IND) with the U.S. Food & Drug Administration (FDA) ... in patients with panic disorder (PD). , "Adding a PD trial to a ...
Breaking Biology Technology:
Cached News: